Preoperative chemoradiation treatment strategies for localized sarcoma

Peter W T Pisters, Matthew Ballo, Shreyaskumar R. Patel

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Background: Over the past 2 decades, there has been increasing interest in chemoradiation treatment strategies for patients with soft tissue sarcomas. Investigators have evaluated: (1) the optimal route for chemotherapy administration (intra-arterial vs. intravenous); (2) the possible advantages of protracted infusion of the radiosensitizer versus brief infusion; (3) the efficacy and toxicity of various intravenous and oral radiation sensitizers; and (4) the efficacy of sequential versus concurrent combined modality treatment. Methods: The English-language literature addressing chemoradiation for localized and locally advanced extremity and retroperitoneal sarcomas was reviewed. Results: All studies have been pilot, phase I, or phase II designs. The most commonly used radiosensitizer for concurrent chemoradiation has been doxorubicin, administered intravenously in most recent reports. In the studies that have included assessment of recurrence-free survival, preoperative chemoradiation combined with surgery has resulted in favorable local control rates, often in excess of 90% for patients with localized and locally advanced extremity sarcomas. Conclusions: The toxicities and recurrence-free outcome with chemoradiation plus surgery for soft tissue sarcoma still need to be compared to these with surgery and pre- or postoperative radiation. However, the generally favorable local control rates reported for chemoradiation justify continued investigation of preoperative chemoradiation strategies for localized sarcoma.

Original languageEnglish (US)
Pages (from-to)535-542
Number of pages8
JournalAnnals of Surgical Oncology
Volume9
Issue number6
DOIs
StatePublished - Jul 25 2002
Externally publishedYes

Fingerprint

Sarcoma
Extremities
Radiation-Sensitizing Agents
Therapeutics
Recurrence
Doxorubicin
Language
Research Personnel
Radiation
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Preoperative chemoradiation treatment strategies for localized sarcoma. / Pisters, Peter W T; Ballo, Matthew; Patel, Shreyaskumar R.

In: Annals of Surgical Oncology, Vol. 9, No. 6, 25.07.2002, p. 535-542.

Research output: Contribution to journalReview article

Pisters, Peter W T ; Ballo, Matthew ; Patel, Shreyaskumar R. / Preoperative chemoradiation treatment strategies for localized sarcoma. In: Annals of Surgical Oncology. 2002 ; Vol. 9, No. 6. pp. 535-542.
@article{0b2b549d5d6443d58c33f10c0a499799,
title = "Preoperative chemoradiation treatment strategies for localized sarcoma",
abstract = "Background: Over the past 2 decades, there has been increasing interest in chemoradiation treatment strategies for patients with soft tissue sarcomas. Investigators have evaluated: (1) the optimal route for chemotherapy administration (intra-arterial vs. intravenous); (2) the possible advantages of protracted infusion of the radiosensitizer versus brief infusion; (3) the efficacy and toxicity of various intravenous and oral radiation sensitizers; and (4) the efficacy of sequential versus concurrent combined modality treatment. Methods: The English-language literature addressing chemoradiation for localized and locally advanced extremity and retroperitoneal sarcomas was reviewed. Results: All studies have been pilot, phase I, or phase II designs. The most commonly used radiosensitizer for concurrent chemoradiation has been doxorubicin, administered intravenously in most recent reports. In the studies that have included assessment of recurrence-free survival, preoperative chemoradiation combined with surgery has resulted in favorable local control rates, often in excess of 90{\%} for patients with localized and locally advanced extremity sarcomas. Conclusions: The toxicities and recurrence-free outcome with chemoradiation plus surgery for soft tissue sarcoma still need to be compared to these with surgery and pre- or postoperative radiation. However, the generally favorable local control rates reported for chemoradiation justify continued investigation of preoperative chemoradiation strategies for localized sarcoma.",
author = "Pisters, {Peter W T} and Matthew Ballo and Patel, {Shreyaskumar R.}",
year = "2002",
month = "7",
day = "25",
doi = "10.1245/aso.2002.9.6.535",
language = "English (US)",
volume = "9",
pages = "535--542",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Preoperative chemoradiation treatment strategies for localized sarcoma

AU - Pisters, Peter W T

AU - Ballo, Matthew

AU - Patel, Shreyaskumar R.

PY - 2002/7/25

Y1 - 2002/7/25

N2 - Background: Over the past 2 decades, there has been increasing interest in chemoradiation treatment strategies for patients with soft tissue sarcomas. Investigators have evaluated: (1) the optimal route for chemotherapy administration (intra-arterial vs. intravenous); (2) the possible advantages of protracted infusion of the radiosensitizer versus brief infusion; (3) the efficacy and toxicity of various intravenous and oral radiation sensitizers; and (4) the efficacy of sequential versus concurrent combined modality treatment. Methods: The English-language literature addressing chemoradiation for localized and locally advanced extremity and retroperitoneal sarcomas was reviewed. Results: All studies have been pilot, phase I, or phase II designs. The most commonly used radiosensitizer for concurrent chemoradiation has been doxorubicin, administered intravenously in most recent reports. In the studies that have included assessment of recurrence-free survival, preoperative chemoradiation combined with surgery has resulted in favorable local control rates, often in excess of 90% for patients with localized and locally advanced extremity sarcomas. Conclusions: The toxicities and recurrence-free outcome with chemoradiation plus surgery for soft tissue sarcoma still need to be compared to these with surgery and pre- or postoperative radiation. However, the generally favorable local control rates reported for chemoradiation justify continued investigation of preoperative chemoradiation strategies for localized sarcoma.

AB - Background: Over the past 2 decades, there has been increasing interest in chemoradiation treatment strategies for patients with soft tissue sarcomas. Investigators have evaluated: (1) the optimal route for chemotherapy administration (intra-arterial vs. intravenous); (2) the possible advantages of protracted infusion of the radiosensitizer versus brief infusion; (3) the efficacy and toxicity of various intravenous and oral radiation sensitizers; and (4) the efficacy of sequential versus concurrent combined modality treatment. Methods: The English-language literature addressing chemoradiation for localized and locally advanced extremity and retroperitoneal sarcomas was reviewed. Results: All studies have been pilot, phase I, or phase II designs. The most commonly used radiosensitizer for concurrent chemoradiation has been doxorubicin, administered intravenously in most recent reports. In the studies that have included assessment of recurrence-free survival, preoperative chemoradiation combined with surgery has resulted in favorable local control rates, often in excess of 90% for patients with localized and locally advanced extremity sarcomas. Conclusions: The toxicities and recurrence-free outcome with chemoradiation plus surgery for soft tissue sarcoma still need to be compared to these with surgery and pre- or postoperative radiation. However, the generally favorable local control rates reported for chemoradiation justify continued investigation of preoperative chemoradiation strategies for localized sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0036062418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036062418&partnerID=8YFLogxK

U2 - 10.1245/aso.2002.9.6.535

DO - 10.1245/aso.2002.9.6.535

M3 - Review article

C2 - 12095968

AN - SCOPUS:0036062418

VL - 9

SP - 535

EP - 542

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -